Verifying…
Home / Drug A–Z / Akobal-G

Akobal-G

NAFDAC Reg. No. B4-2466 · Drug

Registered with NAFDAC. Registration activeAs of 28 October 2026 · synced automatically from official sources.
Product
Akobal-G
NAFDAC number
B4-2466
Active ingredient
Gabapentin; Methylcobalamin
Strength
300 mg; 500 mcg
Form
Capsule
Pack size
10 x 1 x 10's (in Alu-Alu pack)
Manufacturer
Not listed
Applicant (holder)
Akol Healthcare Limited
Approved
27 Jul 2023
Status
Active View on NAFDAC ↗
Registration valid to
26 Jul 2028
WHO alerts
None found
Community reports
None
Times checked
0

What we found

  • Akobal-G is on the NAFDAC register with an active registration (B4-2466). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

What Akobal-G is used for

From the official U.S. FDA label for gabapentin, the active ingredient registered with NAFDAC.

What it is used for

Gabapentin Capsules, USP are indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy Gabapentin Capsules, USP are indicated for Postherpetic neuralgia in adults (1) Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy (1)

Possible side effects

The following serious adverse reactions are discussed in greater detail in other sections: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions (5.1) ] Anaphylaxis and Angioedema [see Warnings and Precautions (5.2) ] Somnolence/Sedation and Dizziness [see see Warnings and Precautions (5.4) ] Withdrawal Precipitated Seizure, Status Epilepticus [see see Warnings and Precautions (5.5) ] Suicidal Behavior and Ideation [see see Warnings and Precautions (5.6) ] Respiratory Depression [see Warnings and Precautions (5.7) ] Neuropsychiatric Adverse Reactions (Pediatric Patients 3 to 12 Years of Age) [ see Warnings and Precautions (5.8 …

Do not use if

Gabapentin is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients. Known hypersensitivity to gabapentin or its ingredients (4)

Warnings

Drug Reaction with Eosinophilia and Systemic Symptoms (Multiorgan hypersensitivity): Discontinue if alternative etiology is not be established (5.1) Anaphylaxis and Angioedema: Discontinue and evaluate patient immediately (5.2) Driving impairment; Somnolence/Sedation and Dizziness: Warn patients not to drive until they have gained sufficient experience to assess whether their ability to drive or operate heavy machinery will be impaired (5.3, 5.4) Increased seizure frequency may occur in patients with seizure disorders if Gabapentin is abruptly discontinued (5.5) Suicidal Behavior and Ideation: Monitor for suicidal thoughts / behavior (5.6) Respiratory depression: May occur with gabapentin wh …

Pregnancy & breastfeeding

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs), such as Gabapentin, during pregnancy. Encourage women who are taking Gabapentin during pregnancy to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling the toll free number 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. …

General information only, not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Akobal-G

Add the expiry date on your pack for a full Trust Score.

3 free checks left today Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Akobal-G

What is in Akobal-G?

Akobal-G contains Gabapentin; Methylcobalamin (300 mg; 500 mcg), as capsule, according to its NAFDAC registration record.

Is Akobal-G registered with NAFDAC?

Yes. Akobal-G is listed on the NAFDAC register under registration number B4-2466, and its registration is active as of 28 October 2026.

Has Akobal-G been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Akobal-G in our automatically synced alert list.

How can I check that my pack of Akobal-G is genuine?

Run a free authenticity scan with the NAFDAC number B4-2466, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Akobal-G used for?

Gabapentin Capsules, USP are indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy Gabapentin Capsules, USP are indicated for Postherpetic neuralgia in adults (1) Adjunctive therapy in the treatment of partial onset seizu (Summarised from the official U.S. FDA label for gabapentin. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Akobal-G? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.